Recent studies have also showed that anti-VEGF therapy can improve anti-PD-L1 (programmed death ligand 1) treatment, especially when it generates intratumoral high endothelial venules (HEVs) that facilitate enhanced cytotoxic T lymphocyte (CTL) infiltration and tumor cell destruction [54]. Here, CD274 is linked to neoplasm.